PHAXIAM Therapeutics SA PXMTF
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 10.05M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.phaxiam.com
Valuation
|
Metric
|
PXMTF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PXMTF
|
|---|---|
Quick Ratio | 1.68 |
Current Ratio | 1.78 |
Interest Coverage | −3.60 |
Quick Ratio
PXMTF
Profitability
|
Metric
|
PXMTF
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PXMTF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!YB>HlR | LOCK|d%@C | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|PCnnlL& | LOCK|Pn>! | $70B | |||
| argenx SE ADR
ARGX
| LOCK|#>R!^< | LOCK|%@@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|WSGmPZ | LOCK|?ZY>l | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r!N!<^ | LOCK|pd | $37B | |||
| Moderna Inc
MRNA
| LOCK|%^@yM& | LOCK|>qH | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|DkR&%<F | LOCK|!F!t | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|%fsL<p? | LOCK|!Qh | $23B | |||
| Incyte Corp
INCY
| LOCK|$Gvbn? | LOCK|$M | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|w?&sL!h | LOCK|J$# | $16B |
United States